SARS-CoV-2 is associated with a 3.4% mortality rate in patients with severe disease. The
pathogenesis of severe cases remains unknown. We performed an in-depth prospective …

Background and Objectives To evaluate the immune-specific response after full severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccination of patients with multiple …

SARS-CoV-2 is a novel coronavirus, not encountered before by humans. The wide spectrum
of clinical expression of SARS-CoV-2 illness suggests that individual immune responses to …

Background Data on SARS-CoV-2 vaccine immunogenicity in PLWH are currently limited.
Aim of the study was to investigate immunogenicity according to current CD4 T-cell count …

The immunological mechanisms underlying the clinical presentation of SARS-CoV-2
infection and those influencing the disease outcome remain to be defined. Myeloid-derived …

Objective To assess in rheumatoid arthritis (RA) patients, treated with different immunosuppressive
therapies, the induction of SARS-CoV-2-specific immune response after vaccination …

Despite the magnitude of the Ebola virus disease (EVD) outbreak in West Africa, there is still
a fundamental lack of knowledge about the pathophysiology of EVD 1 . In particular, very …

Increased production of inflammatory cytokines and myeloid-derived suppressor cells
occurs in patients with coronavirus disease 2019. These inversely correlated with perforin-…

Massive platelet activation and thrombotic events characterize severe COVID-19, highlighting
their critical role in SARS-CoV-2-induced immunopathology. Since there is a well-…

Little evidence on coronavirus disease 2019 (COVID‐19) in people living with HIV (PLWH)
is currently available. We reported clinical and viroimmunological data of all HIV‐positive …